Three months ago we hailed "the steepest price fall since 2007". Now it turns out there was no such thing.
As war drums start to accompany a breakdown in civility in the West, investors should beware.
After reaching a certain percentage holding in Teva, investment funds could begin demanding changes.
Teva's poor results cut short a rally in its share sparked by good clinical results for its migraine headache drug.
Prices will rise again after all the natural gas in Karish and Tanin is sold.
Metal detectors are routinely installed at malls not to mention holy sites at Mecca and Medina. So why not at the Temple Mount?
Continuous treatment of Parkinson's disease will enable patients to tolerate the drugs better for longer.